Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
Sci Rep ; 14(1): 6355, 2024 03 16.
Article En | MEDLINE | ID: mdl-38491009

We aim to determine the safety and efficacy of clevidipine for neurocritical patients. To comprehensively identify relevant studies, a systematic search strategy was employed using the following keywords: "clevidipine", "high blood pressure", "hypertension", "Neuroscience Intensive Care", "neuro critical", and "neurosurgical patients". Searches were conducted in the Clinicaltrials.gov, PubMed, and EuroPMC databases, with the search extending until September 1, 2023. The primary outcomes of interest were the time needed to achieve the target systolic blood pressure (SBP) and the percentage of time a patient remained within the targeted SBP range. Secondary outcomes included SBP values, duration of intensive care unit (ICU) stay in days, rates of hypotension, and rates of tachycardia. We included five retrospective cohort studies (n = 443), utilizing nicardipine as the primary comparator. Comparison of the time to reach target systolic blood pressure (SBP) revealed no significant difference between medications (SMD = - 1.09, p = 0.33). Likewise, the achieved SBP target showed no notable distinction (RR = 1.15, p = 0.81). However, clevidipine exhibited a slightly higher percentage of time within the target SBP range (SMD = 0.33, p = 0.04), albeit with moderate heterogeneity. Importantly, all included studies were retrospective cohort studies, underscoring the methodological context of the investigation. Clevidipine and the control group were found to be comparable in terms of achieving target SBP. Clevidipine may have a slight advantage in maintaining blood pressure within the desired range, but further research is needed to confirm this finding.


Antihypertensive Agents , Hypertension , Pyridines , Humans , Blood Pressure , Antihypertensive Agents/adverse effects , Calcium Channel Blockers/adverse effects , Retrospective Studies , Treatment Outcome , Hypertension/drug therapy
2.
J Med Case Rep ; 11(1): 30, 2017 Feb 04.
Article En | MEDLINE | ID: mdl-28159011

BACKGROUND: Over the past 16 years, sepsis management has been guided by large-volume fluid administration to achieve certain hemodynamic optimization as advocated in the Rivers protocol. However, the safety of such practice has been questioned because large-volume fluid administration is associated with fluid overload and carries the worst outcome in patients with sepsis. Researchers in multiple studies have declared that using less fluid leads to increased survival, but they did not describe how to administer fluids in a timely and appropriate manner. CASE PRESENTATION: An 86-year-old previously healthy Sundanese man was admitted to the intensive care unit at our institution with septic shock, acute kidney injury, and respiratory distress. Standard care was implemented during his initial care in the high-care unit; nevertheless, his condition worsened, and he was transferred to the intensive care unit. We describe the timing of fluid administration and elaborate on the amount of fluids needed using a conservative fluid regimen in a continuum of resuscitated sepsis. CONCLUSIONS: Because fluid depletion in septic shock is caused by capillary leak and pathologic vasoplegia, continuation of fluid administration will drive intravascular fluid into the interstitial space, thereby producing marked tissue edema and disrupting vital oxygenation. Thus, fluids have the power to heal or kill. Therefore, management of patients with sepsis should entail early vasopressors with adequate fluid resuscitation followed by a conservative fluid regimen.


Acute Kidney Injury/therapy , Anti-Bacterial Agents/administration & dosage , Catheters, Indwelling/adverse effects , Critical Care , Fluid Therapy , Shock, Septic/therapy , Vasoconstrictor Agents/administration & dosage , Accidental Falls , Acute Kidney Injury/physiopathology , Aged, 80 and over , Catheters, Indwelling/microbiology , Critical Care/methods , Fluid Therapy/methods , Humans , Intensive Care Units , Male , Neuromuscular Blockade , Practice Guidelines as Topic , Shock, Septic/physiopathology , Treatment Outcome
...